|Study (Ref. #)||Year||Study Population (n)||S-DAPT (Months)||L-DAPT (Months)||Time of Follow-Up∗||Placebo-Controlled||Primary Endpoint||Age (yrs)||DM (%)||ACS (%)||1G-DES (%)||2G-DES (%)|
|3- or 6-month DAPT discontinuation trials|
|ISAR-SAFE (16)||2014||4,000||6||12||6||Yes||Composite of death, MI, stroke, stent thrombosis, or TIMI major bleeding at 15 months after PCI||67||25||40||10||89|
|ITALIC (17)||2014||1,822||6||12||6||No||Composite of death, MI, repeat TVR, stroke, or TIMI major bleeding at 12 months after PCI||62||37||24||—||100†|
|SECURITY (18)||2014||1,399||6||12||12‡||No||Composite of cardiac death, MI, stroke, stent thrombosis, or BARC 3 or 5 bleeding at 12 months after PCI||65||31||38§||—||100|
|OPTIMIZE (15)||2014||3,119||3||12||12||No||Composite of death, MI, stroke, or major bleeding at 12 months after PCI||62||35||32§||—||100|
|PRODIGY (20)||2012||1,970||6||24||23||No||Composite of death, MI, or cerebrovascular accidents at 24 months after PCI||68||24||75||25||50|
|EXCELLENT (19)||2011||1,443||6||12||12||No||Composite of cardiac death, MI, or TVR at 12 months after PCI||63||38||52||25||75|
|RESET (14)||2012||2,117||3||12||12||No||Composite of cardiac death, MI, stent thrombosis, ischemia-driven TVR, or bleeding at 12 months after PCI||62||29||54||21||85‖|
|12-month DAPT discontinuation trials|
|DAPT (7)||2014||9,961||12||30||21||Yes||Stent thrombosis; composite of death, MI, or stroke; and moderate or severe GUSTO bleeding; at 18 months after randomization||62||31||43||38||60|
|DES-LATE (22)||2014||5,045||12||36||42||No||Composite of cardiac death, MI, or stroke at 24 months after randomization||62||28||61||64||30|
|ARCTIC-Interruption (21)||2014||1,259||12||18–30||17||No||Composite of death, MI, stroke or TIA, urgent revascularization, or stent thrombosis||64||34||—||40||63|
1G = first-generation; 2G = second-generation; ACS = acute coronary syndrome; ARCTIC-Interruption = Dual-Antiplatelet Treatment Beyond 1 Year After Drug-Eluting Stent Implantation; BARC = Bleeding Academic Research Consortium; DAPT = dual antiplatelet therapy; DES = drug-eluting stent; DES-LATE = Duration of Clopidogrel Therapy After Drug-Eluting Stent; DM = diabetes mellitus; EXCELLENT = Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting; GUSTO = Global Use of Strategies to Open Occluded Arteries; ISAR-SAFE = Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting; ITALIC = Is There A Life for DES After Discontinuation of Clopidogrel; L-DAPT = longer dual antiplatelet therapy; MI = myocardial infarction; OPTIMIZE = Optimized Duration of Clopidogrel Therapy Following Treatment With the Zotarolimus-Eluting Stent in Real-World Clinical Practice; PCI = percutaneous coronary intervention; PRODIGY = Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study; RESET = REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation; S-DAPT = shorter dual antiplatelet therapy; SECURITY = Second Generation Drug-Eluting Stent Implantation Followed by Six- Versus Twelve-Month Antiplatelet Therapy; TIA = transient ischemic attack; TIMI = Thrombolysis In Myocardial Infarction; TVR = target vessel revascularization.
↵∗ Refers to follow-up time from randomization (Online Figure 1 and Figure 2).
↵† Only Xience V everolimus-eluting stent.
↵‡ Maximum length of follow-up was 24 months; however, maximum duration of DAPT was 12 months. In the analyses, outcomes at 12 months have been included.
↵§ High-risk acute coronary syndromes excluded.
↵‖ 100% Endeavor zotarolimus-eluting stent in the 3-month group.